Literature DB >> 18646107

Vitamin B for treating peripheral neuropathy.

Cynthia D Ang1, Maria Jenelyn M Alviar, Antonio L Dans, Gwyneth Giselle P Bautista-Velez, Maria Vanessa C Villaruz-Sulit, Jennifer J Tan, Homer U Co, Maria Rhida M Bautista, Artemio A Roxas.   

Abstract

BACKGROUND: Vitamin B is frequently used for treating peripheral neuropathy but its efficacy is not clear.
OBJECTIVES: The objective of this review was to assess the effects of vitamin B for treating generalised peripheral neuropathy. SEARCH STRATEGY: We searched the Cochrane Neuromuscular Disease Group Trials Register (searched August 2005), MEDLINE (January 1966 to September 2005), EMBASE (January 1980 to September 2005), Philippine databases (searched September 2005) and reference lists of articles. We also contacted manufacturers and researchers in the field. SELECTION CRITERIA: Randomised and quasi-randomised trials where vitamin B was compared with placebo or another treatment in generalised peripheral neuropathy. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. We contacted study authors for additional information. MAIN
RESULTS: Thirteen studies involving 741 participants with alcoholic or diabetic neuropathy were included. In the comparison of vitamin B with placebo, two small trials showed no significant short-term benefit in pain intensity while one of the trials showed a small significant benefit in vibration detection from oral benfotiamine, a derivative of thiamine. In the larger of two trials comparing different doses of vitamin B complex, there was some evidence that higher doses resulted in a significant short-term reduction in pain and improvement in paraesthesiae, in a composite outcome combining pain, temperature and vibration, and in a composite outcome combining pain, numbness and paraesthesiae. There was some evidence that vitamin B is less efficacious than alpha-lipoic acid, cilostazol or cytidine triphosphate in the short-term improvement of clinical and nerve conduction study outcomes but the trials were small. There were few minor adverse effects reported. AUTHORS'
CONCLUSIONS: There are only limited data in randomised trials testing the efficacy of vitamin B for treating peripheral neuropathy and the evidence is insufficient to determine whether vitamin B is beneficial or harmful. One small trial in alcoholic peripheral neuropathy reported slightly greater improvement in vibration perception threshold with oral benfotiamine for eight weeks than placebo. In another small study, a higher dose of oral vitamin B complex for four weeks was more efficacious than a lower dose in reducing symptoms and signs. Vitamin B administered by various routes for two to eight weeks was less efficacious than alpha-lipoic acid, cilostazol or cytidine triphosphate in short-term improvement of clinical and nerve conduction study outcomes. Vitamin B is generally well-tolerated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18646107     DOI: 10.1002/14651858.CD004573.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  32 in total

Review 1.  Drug therapy for chronic idiopathic axonal polyneuropathy.

Authors:  Janna Warendorf; Alexander Fje Vrancken; Ivo N van Schaik; Richard Ac Hughes; Nicolette C Notermans
Journal:  Cochrane Database Syst Rev       Date:  2017-06-20

2.  Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages.

Authors:  Mohammad Shoeb; Kota V Ramana
Journal:  Free Radic Biol Med       Date:  2011-10-24       Impact factor: 7.376

3.  Non-invasive therapy for altered facial sensation following orthognathic surgery: an exploratory randomized clinical trial of intranasal vitamin B12 spray.

Authors:  C Phillips; G K Essick; Y Chung; G Blakey
Journal:  J Maxillofac Trauma       Date:  2012-04-01

4.  Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir.

Authors:  Romain Coriat; Jérôme Alexandre; Carole Nicco; Laurent Quinquis; Evelyne Benoit; Christiane Chéreau; Hervé Lemaréchal; Olivier Mir; Didier Borderie; Jean-Marc Tréluyer; Bernard Weill; Joel Coste; François Goldwasser; Frédéric Batteux
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

Review 5.  Emerging Concepts in Nutrient Needs.

Authors:  Patrick J Stover; Cutberto Garza; Jane Durga; Martha S Field
Journal:  J Nutr       Date:  2020-10-01       Impact factor: 4.798

Review 6.  Exercise intervention studies in patients with peripheral neuropathy: a systematic review.

Authors:  Fiona Streckmann; Eva M Zopf; Helmar C Lehmann; Kathrin May; Julia Rizza; Philipp Zimmer; Albert Gollhofer; Wilhelm Bloch; Freerk T Baumann
Journal:  Sports Med       Date:  2014-09       Impact factor: 11.136

7.  [Thiamine, pyridoxine and cobalamine. From myths to pharmacology and clinical practice].

Authors:  S Jesse; A C Ludolph
Journal:  Nervenarzt       Date:  2012-04       Impact factor: 1.214

8.  A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).

Authors:  Janet M Schloss; Maree Colosimo; Caroline Airey; Paul Masci; Anthony W Linnane; Luis Vitetta
Journal:  Support Care Cancer       Date:  2016-09-09       Impact factor: 3.603

9.  Experimental model of alcohol-related peripheral neuropathy.

Authors:  Michelle L Mellion; Vananh Nguyen; Ming Tong; James Gilchrist; Suzanne De La Monte
Journal:  Muscle Nerve       Date:  2013-06-13       Impact factor: 3.217

10.  Thiamine, riboflavin, and nicotinamide inhibit paclitaxel-induced allodynia by reducing TNF-α and CXCL-1 in dorsal root ganglia and thalamus and activating ATP-sensitive potassium channels.

Authors:  Alysson V Braga; Sarah O A M Costa; Felipe F Rodrigues; Ivo S F Melo; Marcela I Morais; Márcio M Coelho; Renes R Machado
Journal:  Inflammopharmacology       Date:  2019-08-06       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.